LEADER trial
Also written as: LEADER — Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Pivotal cardiovascular outcomes trial that demonstrated cardiovascular benefits of liraglutide in type 2 diabetes.
Full Definition
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial was a landmark randomized controlled trial that evaluated cardiovascular outcomes with liraglutide versus placebo in patients with type 2 diabetes at high cardiovascular risk. The trial demonstrated a significant 13% reduction in major adverse cardiovascular events with liraglutide treatment. LEADER was one of the first cardiovascular outcomes trials to show cardiovascular benefits with a GLP-1 receptor agonist, leading to regulatory approval for cardiovascular indication. The trial's positive results fundamentally changed diabetes treatment paradigms and influenced subsequent guideline recommendations for patients with established cardiovascular disease or high cardiovascular risk.
Usage
Usage note: First major positive CVOT for GLP-1 class; spell out full name on first use
In Context
- "The LEADER trial established liraglutide as a cardioprotective diabetes medication." — Clinical guideline
- "Following LEADER trial results, GLP-1 agonists gained cardiovascular indications." — Regulatory document